



NIH AIDS Reagent Program

20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

Reagent: HIV-1 pNL4-3.HSA.R+E-

Catalog Number: 3420

Lot Number: 110146

Release Category: C

Provided: 5 µg of dried purified DNA stabilized in DNASTable *PLUS*

Cloning Vector: pUC-19
Ampicillin resistant

Description: Env- due to a 5' frameshift. Murine heat stable antigen CD24 (HSA) gene was inserted into the pNL4-3 nef gene.

Special Characteristics: This construct is 14,973 bp including the insert.
Competent for a single round of replication. Requires cotransfection with env expression vector to produce infectious virus.
[Contributor provided protocol and sequence information](#)
[Plasmid map and sequence file lot 110146](#)
This reagent is currently being provided as dried purified DNA stabilized in DNASTable *PLUS*. Please see the notice for additional information and the protocol for reconstitution of dried DNA reagents. [Dried DNA Notice](#)

Recommended Storage: Keep the reagent at room temperature in a dry storage cabinet or in a moisture barrier bag.

Contributor: Dr. Nathaniel Landau, Aaron Diamond AIDS Research Center, The Rockefeller University.

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

References:

He J, Choe S, Walker R, Di Marzio P, Morgan DO, Landau NR. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. *J Virol* **69**: 6705–6711, 1995.[Abstract](#)

Connor RI, Chen BK, Choe S, Landau NR. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. *Virology* **206**: 935–944, 1995.[Abstract](#)

NOTE:

Acknowledgment for publications should read “The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: pNL4-3.HSA.R+E-from Dr. Nathaniel Landau.” Also include the references cited above in any publications.

Patent pending. Requests from commercial organizations must be directed to the New York University Office of Industrial Liaison at the following email address: sadhana.chitale@nyumc.org.

Last Updated

June 19, 2017

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.